From: Soluble OX40L is associated with presence of autoantibodies in early rheumatoid arthritis
Characteristics | Early rheumatoid arthritis PLA (n = 37) | Early rheumatoid arthritis ADA (n = 39) | Chronic rheumatoid arthritis (n = 15) | Healthy volunteers (n = 34) |
---|---|---|---|---|
Age, years | 54 (37 to 65) | 56 (38 to 62) | 56 (45 to 64) | 54 (38 to 62) |
Gender, % female | 78 | 64 | 80 | 67 |
Disease duration at inclusion, months | 2.7 (1.4 to 4.3) | 2.9 (1.6 to 4.4) | 234 (120 to 342) | NA |
Disease scores | ||||
DAS28 score, baseline | 5.6 (4.9 to 5.8) | 5.4 (4.8 to 6.4) | 3.0 (2.2 to 3.9) | NA |
DAS28 score, 3 months | 2.3 (1.9 to 2.9) | 2.0 (1.8 to 2.7) | NA | NA |
DAS28 score, 12 months | 2.2 (1.9 to 3.4) | 1.9 (1.8 to 2.5) | NA | NA |
Remission, 12 months, % | 56 | 52 | NA | NA |
HAQ score, baseline, range 0 to 3 | 0.9 (0.6 to 1.3) | 1.1 (0.8 to 1.5) | 1.0 (0.2 to 2.0) | NA |
HAQ score, 3 months, range 0 to 3 | 0.1 (0.0 to 0.6) | 0.2 (0.0 to 0.38) | NA | NA |
HAQ score, 12 months, range 0 to 3 | 0.1 (0 to 0.5) | 0.0 (0.0 to 0.4) | NA | NA |
Treatment dose | ||||
MTX, 12 months, mg/week | 20.0 (15.5 to 20.0) | 20.0 (18.8 to 20.0) | NA | NA |
Cumulative dose of intra-articular betamethasone, 12 months, ml | 8.0 (5.0 to 12.5) | 5.0 (3.0 to 10.0) | NA | NA |
Laboratory findings at baseline | ||||
IgM-RF-positive, % | 84 | 67 | 74 | NA |
ACPA-positive, % | 81 | 56 | 74 | NA |